Alithea Genomics Signs Deal with Revvity to Scale Transcriptomic Profiling in Drug Discovery

For R&D organizations building early-stage discovery pipelines, the integration of high-throughput transcriptomic profiling into compound screening workflows has remained a logistical bottleneck. Alithea Genomics and Revvity have moved to address that gap directly, announcing a collaboration that embeds Alithea's MERCURIUS DRUG-seq platform within Revvity's established screening portfolio.

MERCURIUS DRUG-seq is designed for bulk RNA sequencing at scale, enabling simultaneous transcriptomic readouts across large compound libraries. The integration with Revvity's infrastructure extends distribution and technical support reach globally, lowering the operational barrier for discovery teams that lack in-house sequencing capacity or bioinformatics pipelines capable of handling the data volumes involved.

For drug discovery leads, the practical consequence is access to genome-wide expression profiling earlier in the screening cascade. Rather than relying on targeted assays that measure a limited set of biomarkers, DRUG-seq-based workflows generate mechanism-of-action signatures across thousands of genes per compound, data that feeds directly into AI-driven target identification models. The relevance for computational biology teams is sharper here: richer transcriptomic datasets reduce the feature sparsity that limits model performance in early hit-to-lead work.

Revvity's existing position in life science instrumentation and reagent distribution gives the collaboration immediate geographic reach across North America, Europe, and Asia-Pacific. For research organizations operating under ICH Q8 quality-by-design frameworks, the ability to source a validated, commercially supported transcriptomics workflow through an established vendor simplifies both procurement and method qualification documentation.

The collaboration does not disclose financial terms, milestone structures, or a specific timeline for full portfolio integration, leaving open questions around how quickly MERCURIUS DRUG-seq will be available through Revvity's standard ordering channels and what technical transfer or co-development commitments underpin the arrangement.

The measurable outcome to track is adoption rate among CROs and pharma discovery units that currently outsource transcriptomic profiling, as consolidated vendor access through Revvity could shift that outsourcing calculus within the next procurement cycle.

Source: Media4Growth via Indian Pharma Post, 15 June 2026.